Antibiotic treatment strategies for Helicobacter pylori infection

Sma Campo, A Zullo, Cesare Hassan, S. Morini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.
Original languageEnglish
Pages (from-to)11-17
Number of pages7
JournalRecent Patents on Anti-Infective Drug Discovery
Volume2
Publication statusPublished - 2007
Externally publishedYes

Keywords

  • Animals
  • Anti-Bacterial Agents
  • Helicobacter Infections
  • Helicobacter pylori
  • Humans
  • Microbial Sensitivity Tests
  • Patents as Topic
  • Stomach Ulcer

Fingerprint

Dive into the research topics of 'Antibiotic treatment strategies for Helicobacter pylori infection'. Together they form a unique fingerprint.

Cite this